Market Overview:
The global urothelial cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of urothelial cancer, rising awareness about urothelial cancer and its treatment options, and technological advancements in the field of oncology. Based on type, the global urothelial cancer drugs market can be segmented into chemotherapy and immunotherapy. Chemotherapy is currently the most commonly used treatment for urothelial cancers and is expected to dominate the market during the forecast period. Immunotherapy is also gaining popularity as a treatment option for these cancers due to its ability to target specific molecules present on tumor cells. Based on application, hospitals are currently accounting for a majority share of the global urothelial cancer drugs market. However, pharmacy is expected to witness higher growth rates duringthe forecast period owingto increasing demand for generic versions of branded drugs and growing preference for home-based care among patients diagnosed with advanced stages ofcancer .
Product Definition:
Urothelial cancer drugs are a type of medication used to treat cancers that originate in the cells lining the urinary tract. These medications can help to shrink tumors, slow their growth, or stop them from spreading. Additionally, they may be able to improve symptoms associated with the cancer such as pain and difficulty urinating.
Chemotherapy:
Chemotherapy is the use of drugs or other substances to treat cancer. Chemotherapies are used to stop or slow down the growth of cancer cells. They can also make the disease easier to treat by decreasing pain and side effects. Some chemotherapy drugs can shrink tumors, but it usually doesn’t hurt them much more than healthy tissues since most chemotherapies only affect rapidly dividing cells (cells that are growing quickly).
Immunotherapy:
Immunotherapy is a treatment wherein the body's immune system is activated to fight cancerous cells. There are various types of immunotherapies, including checkpoint inhibitors, tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor (CAR) T cell therapy, and CD20 antibody therapies.
Urothelial Cancer Drugs Market Size & Forecast by Type of Immunotherapy 2018 - 2023 -> The global immunotherapy market size was valued at USD 6.
Application Insights:
The global market is segmented by application into hospitals and pharmacies. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities and a large patient base for urothelial cancer drugs. The presence of key players such as Pfizer, Inc., Merck KGaA, Roche Ltd., Novartis AG, sanofi Aventis; along with a well-established healthcare infrastructure in North America and Europe contribute to the hospital segment¢â‚¬â„¢s largest share.
Pharmacies are anticipated to be the fastest-growing segment over the forecast period due to increasing awareness about affordable medicines among patients as well as their families. Increasing number of retail outlets coupled with growing demand for generic medicines is expected fuel this growth during future years. In addition, favorable government regulations regarding online pharmacy operations are further likely to propel industry expansion over next few years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high R&D investment by companies and increased healthcare expenditure in this region. Moreover, increasing incidence of urothelial cancer is also contributing toward regional growth. For instance, as per statistics provided by American Cancer Society (ACS), it was estimated that around 17,720 new cases were diagnosed in U.S. in 2018 and more than 469 deaths were reported due to this disease during the same year which are higher than previous years (source).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing awareness about early diagnosis among patients especially from China & Japan countries resulting into faster treatment procedure thus driving demand for drugs used for treating urothelial cancer locally as well as globally thereby positively influencing market growth across regions mentioned above [Figure 1].
Growth Factors:
- Increasing incidence of urothelial cancer
- Growing demand for better and more effective drugs for the treatment of urothelial cancer
- Rising awareness about urothelial cancer and its treatment options
- Technological advancements in the field of drug development
- Availability of government funding for research on urothelial cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Urothelial Cancer Drugs Market Research Report
By Type
Chemotherapy, Immunotherapy
By Application
Hospitals, Pharmacy
By Companies
Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Urothelial Cancer Drugs Market Report Segments:
The global Urothelial Cancer Drugs market is segmented on the basis of:
Types
Chemotherapy, Immunotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Merck
- Bristol-Myers Squibb
- AstraZeneca
- Pfizer
Highlights of The Urothelial Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Immunotherapy
- By Application:
- Hospitals
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urothelial Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Urothelial cancer drugs are medications that are used to treat urothelial cancer. These drugs can help to shrink or stop the growth of tumors in the bladder, and may also help to improve symptoms related to urothelial cancer.
Some of the major companies in the urothelial cancer drugs market are Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Pfizer.
The urothelial cancer drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urothelial Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Urothelial Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Urothelial Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Urothelial Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Urothelial Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Urothelial Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Urothelial Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Urothelial Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Urothelial Cancer Drugs Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Urothelial Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Urothelial Cancer Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urothelial Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urothelial Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Urothelial Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Urothelial Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Urothelial Cancer Drugs Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Immunotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Urothelial Cancer Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Urothelial Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Urothelial Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Urothelial Cancer Drugs Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Immunotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Urothelial Cancer Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Urothelial Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Urothelial Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Urothelial Cancer Drugs Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Immunotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Urothelial Cancer Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Urothelial Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Urothelial Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Urothelial Cancer Drugs Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Immunotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Urothelial Cancer Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Urothelial Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Urothelial Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Urothelial Cancer Drugs Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Immunotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Urothelial Cancer Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urothelial Cancer Drugs Market: Competitive Dashboard
14.2 Global Urothelial Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Merck
14.3.3 Bristol-Myers Squibb
14.3.4 AstraZeneca
14.3.5 Pfizer
